Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.35 |
| ▸ | MOGAT2 | Q3SYC2 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2135223 | 0.88 | LMNA (0.42) | ALDH1A1LMNAPKMSLC40A1PTGES2 | |
| SCHEMBL2137054 | 0.87 | SLC40A1 (0.41) | ALDH1A1LMNAKDM4EPKMSLC40A1 | |
| SCHEMBL2133452 | 0.87 | CCR2 (0.39) | BRD4ALDH1A1LMNAKDM4EPKM | |
| SCHEMBL2135831 | 0.87 | TRPV1 (0.38) | — | |
| SCHEMBL2137469 | 0.86 | MEN1 (0.40) | MCL1LMNAPKMSLC40A1PTGES2 | |
| SCHEMBL2135729 | 0.85 | PSIP1 (0.36) | ALDH1A1MOGAT2 | |
| SCHEMBL2134698 | 0.85 | PTK2B (0.45) | MCL1BRD4ALDH1A1LMNAKDM4E | |
| SCHEMBL2136563 | 0.84 | BRD4 (0.43) | BRD4SLC22A12IDH1LMNAPKM | |
| SCHEMBL2615616 | 0.83 | BRD4 (0.36) | BRD4SLC22A12IDH1ALDH1A1LMNA | |
| SCHEMBL16239846 | 0.82 | ALDH1A1 (0.38) | BRD4ALDH1A1LMNAKDM4EHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | claimed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | claimed |
| EP-2630124-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-08-28 | — | — | EP | claimed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | claimed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | claimed |
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2630124-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-08-28 | — | — | EP | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | PRKAG1, PRKAB1, PRKAG2 | MCL1 1280/4885BRD4 739/4885SLC22A12 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.